{"id":206068,"date":"2017-02-08T14:49:51","date_gmt":"2017-02-08T19:49:51","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/nuance-boosts-bookings-on-healthcare-automotive-demand-fox-business.php"},"modified":"2017-02-08T14:49:51","modified_gmt":"2017-02-08T19:49:51","slug":"nuance-boosts-bookings-on-healthcare-automotive-demand-fox-business","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/health-care\/nuance-boosts-bookings-on-healthcare-automotive-demand-fox-business.php","title":{"rendered":"Nuance Boosts Bookings on Healthcare, Automotive Demand &#8211; Fox Business"},"content":{"rendered":"<p><p>    Nuance Communications (NASDAQ: NUAN) has built up    considerable expertise in turning voice commands into    recognizable actions, and the company is working hard at    expanding the breadth of applications for its cutting-edge    technology. Increasingly, Nuance has sought to make many    different tasks easier, whether it's transcribing doctors'    notes into electronic medical records or having automobile    entertainment systems understand commands from drivers. Coming    into Tuesday's fiscal first-quarter financial report, Nuance    investors were prepared for slight declines in revenue and    earnings per share, but the company managed to score a slight    sales gain on big gains in new bookings.  <\/p>\n<p>    Let's take a closer look at Nuance Communications to see how it    did and what it sees ahead for its business in 2017 and beyond.  <\/p>\n<p>    Image source: Nuance.  <\/p>\n<p>    Nuance's fiscal first-quarter results were relatively close to    what most of those following the stock had expected. Adjusted    revenue climbed by less than 1% to $496 million, but that was    still better than the consensus forecast for a decline to $490    million. On a GAAP basis, Nuance's net loss nearly doubled from    year-ago levels, but after accounting for various extraordinary    items, adjusted earnings of $0.35 per share matched up exactly    with what most investors were looking to see.  <\/p>\n<p>    Taking a closer look at Nuance's numbers, the figure that    stands out the most was the 23% growth in net new bookings,    which hit $380.3 million. Nuance attributed the increase to    healthcare and mobile, and it specifically called out the    Dragon Medical One platform and integrated clinical    documentation solutions as driving the growth.  <\/p>\n<p>      Continue Reading Below    <\/p>\n<p>      ADVERTISEMENT    <\/p>\n<p>    From a segment perspective, the enterprise segment was the key    driver of revenue growth, posting a 15% rise in organic sales    for the segment. However, the rest of the company didn't share    that success. The smaller imaging business had the worst    results, seeing organic sales fall 15%. The key healthcare    segment saw organic revenue decline 6% from year-ago levels,    and the mobile division suffered a 5% drop.  <\/p>\n<p>    Segment profits showed similar patterns. Enterprise was the    only division to post growth in its segment bottom line, while    minimal declines in profitability for healthcare and mobile    paled in comparison to a one-third plunge in the imaging    segment's adjusted profit.  <\/p>\n<p>    Nuance has worked hard to boost recurring revenue, and its slow    growth continued during the quarter. Recurring revenue made up    73% of adjusted sales during the quarter, up six percentage    points from the fiscal first quarter of 2016. By contrast,    perpetual product and licensing revenue saw its decrease    accelerate, falling by nearly a third from the year-ago    quarter.  <\/p>\n<p>    CFO Dan Tempesta was straightforward in his description of the    company's success. \"Nuance delivered strong performance against    our guidance in the first quarter,\" Tempesta said, \"as we    continued our execution and momentum across the business.\" The    CFO pointed to \"solid results\" in bookings, sales, profit, and    cash flow as signs of the progress that Nuance has made.  <\/p>\n<p>    Nuance now thinks that it should be able to start seeing more    impressive revenue gains. In Tempesta's words, \"Last quarter's    groundwork and a robust outlook for the second quarter place    the company on track for our FY17 non-GAAP guidance with a    return to organic revenue growth and continued strong cost    discipline and profitability.\"  <\/p>\n<p>    In particular, Nuance reiterated its guidance for the full 2017    fiscal year. Bookings should sustain growth of 2% to 6%    compared to fiscal 2016, and organic growth in sales should    amount to about 1% for the year. Recurring revenue should stay    at its current level of around 72% to 73% of total revenue,    which will be between $2.02 billion to $2.07 billion and    produce adjusted earnings of $1.53 to $1.63 per share.  <\/p>\n<p>    Fiscal second-quarter predictions from Nuance were very much in    line with investor expectations. The company sees adjusted    sales of $493 million to $507 million, producing adjusted    earnings of $0.36 to $0.40 per share. The consensus forecast    among those following the stock is at the midpoint of both    ranges.  <\/p>\n<p>    Perhaps as a result, Nuance investors didn't have a huge    response to the news, with only the smallest of gains in    after-hours trading following the announcement. If Nuance can    continue to find its way into more breakthrough technologies    going forward, then it will have a better chance at producing    the growth that investors really want to see in the months and    years to come.  <\/p>\n<p>    10 stocks we like better than Nuance    Communications    When investing geniuses David and Tom Gardner have a stock tip,    it can pay to listen. After all, the newsletter they have run    for over a decade, Motley Fool Stock Advisor, has    tripled the market.*  <\/p>\n<p>    David and Tom just revealed what they believe are the 10 best stocks for    investors to buy right now... and Nuance Communications wasn't    one of them! That's right -- they think these 10 stocks are    even better buys.  <\/p>\n<p>    Click here to learn about    these picks!  <\/p>\n<p>    *Stock Advisor returns as of February 6,    2017<\/p>\n<p>    Dan Caplinger has no position in any stocks    mentioned. The Motley Fool recommends Nuance Communications.    The Motley Fool has a disclosure policy.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See the original post here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.foxbusiness.com\/markets\/2017\/02\/07\/nuance-boosts-bookings-on-healthcare-automotive-demand.html\" title=\"Nuance Boosts Bookings on Healthcare, Automotive Demand - Fox Business\">Nuance Boosts Bookings on Healthcare, Automotive Demand - Fox Business<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Nuance Communications (NASDAQ: NUAN) has built up considerable expertise in turning voice commands into recognizable actions, and the company is working hard at expanding the breadth of applications for its cutting-edge technology. Increasingly, Nuance has sought to make many different tasks easier, whether it's transcribing doctors' notes into electronic medical records or having automobile entertainment systems understand commands from drivers. Coming into Tuesday's fiscal first-quarter financial report, Nuance investors were prepared for slight declines in revenue and earnings per share, but the company managed to score a slight sales gain on big gains in new bookings.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/health-care\/nuance-boosts-bookings-on-healthcare-automotive-demand-fox-business.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[6],"tags":[],"class_list":["post-206068","post","type-post","status-publish","format-standard","hentry","category-health-care"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/206068"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=206068"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/206068\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=206068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=206068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=206068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}